Prothena (PRTA) shares rallied 15% in the last trading session to close at $17.59. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 23.7% loss over the past four weeks.Prothena owns a robust Alzheimer's Disease (“AD”) pipeline that spans next-generation antibody immunotherapy, small molecules and vaccines. The pipeline progress has been encouraging. PRTA's collaboration with bigwigs like Roche and Bristol Myer ...

Prothena (PRTA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. The power of a changing e ...

Prothena Corporation (PRTA) reported earnings per share of $1.22 per share in the second quarter of 2024, and the Zacks Consensus Estimate for the same was pegged at a loss of $1.01 per share. In the year-ago quarter, the company posted a loss of $1.03 per share. The upside in earnings was driven by higher revenues. Revenues totaled $132 million, which beat the Zacks Consensus Estimate of $22 million and improved significantly from $4 million in the year-ago quarter. Collaboration fees recognized under an a ...

Prothena (PRTA) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of a loss of $1.01 per share. This compares to loss of $1.03 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 220.79%. A quarter ago, it was expected that this drug developer would post a loss of $1.21 per share when it actually produced a loss of $1.34, delivering a surprise of -10.74%. Over the last four quarters, the co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q _____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 ______________________________________ PROTHENA CORPORATION PUBLIC LIMITED COMP ...

Financial Performance - Prothena reported net income of $66.9 million for Q2 2024, compared to a net loss of $54.6 million in Q2 2023[5]. - Total revenue for Q2 2024 was $132.0 million, a significant increase from $4.0 million in Q2 2023, primarily driven by collaboration revenue from Bristol Myers Squibb[6]. - Basic net income per share for the three months ended June 30, 2024, was $1.24, compared to a loss of $1.03 per share in the same period of 2023[13]. - The company reported a basic net income per share of $1.24 for the six months ended June 30, 2024, compared to a loss of $0.10 per share in the same period of 2023[13]. Cash and Assets - Cash position at the end of Q2 2024 was $565.0 million, with an updated year-end cash guidance of approximately $468 million, an increase of $63 million from prior guidance[1][10]. - Total assets decreased to $645,565,000 as of June 30, 2024, from $696,382,000 as of June 30, 2023[14]. - Total liabilities decreased significantly to $63,648,000 as of June 30, 2024, from $135,017,000 as of June 30, 2023[14]. - Total shareholders' equity increased to $581,917,000 as of June 30, 2024, compared to $561,365,000 as of June 30, 2023[14]. Expenses - Research and development (R&D) expenses for Q2 2024 totaled $57.5 million, slightly up from $56.0 million in Q2 2023, primarily due to higher clinical trial expenses[7]. - General and administrative (G&A) expenses for Q2 2024 were $16.1 million, compared to $14.5 million in Q2 2023, reflecting higher personnel and consulting expenses[8]. - Operating expenses for the three months ended June 30, 2024, totaled $73,637,000, up from $70,523,000 in the same period of 2023[13]. - Total other income for the three months ended June 30, 2024, was $6,470,000, compared to $7,603,000 in the same period of 2023[13]. Clinical Trials and Collaborations - Prothena plans to initiate a Phase 1 clinical trial for PRX019 by the end of 2024, following the exclusive global license agreement with Bristol Myers Squibb for $80 million[3][4]. - Topline results from the ongoing Phase 1 ASCENT program for PRX012 and the confirmatory Phase 3 AFFIRM-AL clinical trial for birtamimab are expected within the next 12 months[2][3]. - The ongoing Phase 2 clinical trial for ATTR cardiomyopathy, conducted by Novo Nordisk, has completed enrollment of approximately 99 patients, with topline data expected in 1H 2025[5]. - Prothena's collaboration with Bristol Myers Squibb includes potential additional milestone payments of up to $617.5 million for PRX019[3]. Future Projections - The company expects to end 2024 with an estimated net loss of $120 to $135 million, including approximately $48 million of non-cash share-based compensation expense[10].

The market expects Prothena (PRTA) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. Zacks Consensus Estimate Estimate Revisions Trend The consensus EPS estimate for the quarter has remained unchanged over the last 30 da ...

A month has gone by since the last earnings report for Prothena (PRTA) . Shares have lost about 1.5% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Prothena due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Prothena Q1 Earnings Miss Estimates on Higher R&D Expense ...

Prothena Corporation plc (PRTA) announced that Bristol Myers (BMY) has in-licensed exclusive global rights to PRX019, a potential treatment option for certain neurodegenerative diseases. PRX019 is the second candidate that has been in-licensed by Bristol Myers under its existing collaboration agreement with PRTA. Prothena anticipates initiating an early-stage study of the candidate by the end of 2024. Bristol Myers' decision to exercise its option for the exclusive global license for PRX019 follows the FDA ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q _____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 ______________________________________ PROTHENA CORPORATION PUBLIC LIMITED COM ...